Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 8 Publications

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NFXsOVBHfW6ldHnvckBCe3OjeR?= M{flUlAvPcLizszN MWSyOEBp MXv3ZZRmeg>? NVfy[FJodW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? MlTTNlUyOjNyOEK=
Eca109 NHTjOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqyNE42NzJwNT:1JO69VQ>? NHXGeWkzPC92OD:3NkBp MVT3ZZRmeg>? NF;WS5FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M17tSVI2OTJ|MEiy
Eca109 NWG0UHAyTnWwY4Tpc44hSXO|YYm= NWDTfJp7OC53wrFOwG0> NXzlWVVnPi9zMj:yOEBp MoW5e4F1\XJ? NIOyRXFqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg M13melI2OTJ|MEiy
Eca109 MmLKSpVv[3Srb36gRZN{[Xl? NETrb4oxNjYEoN88US=> MX[yOEBp Mo\Fe4F1\XJ? M4PQZolvcGmkaYTzJINmdGxiaX72ZZNqd25? MVWyOVEzOzB6Mh?=
Eca109 M3H6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nhd|AvPcLizszN M1voWVI1KGh? M4foT5difGW{ NGXldGpqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm Mo\MNlUyOjNyOEK=
Eca109 NYjY[4hDTnWwY4Tpc44hSXO|YYm= M32xXlAvPS9zIN88US=> NV7kNXFQOjRiaB?= NV\MN5ZRf2G2ZYK= NYfEUpdY\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= Mo\4NlUyOjNyOEK=
SW1116  NY\kS|RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMlUwOS9{L{Wg{txO NGi2eGM1QCCq NEDDdGVFVVOR MoLh[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MUiyOFg4PDJ6Nh?=
LOVO MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPib4Q5OC53L{GvNk82KM7:TR?= MmHHOFghcA>? MmntSG1UVw>? MlXU[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> Mnr1NlQ5PzR{OE[=
SW1116  NWPWOXNoTnWwY4Tpc44hSXO|YYm= MmToNVAh|ryP MWG0PEBp NFHTUlRFVVOR NHz5N4xqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NYWzcllqOjR6N{SyPFY>
LOVO NY\Y[IxLTnWwY4Tpc44hSXO|YYm= MoTDNVAh|ryP MoH4OFghcA>? NYjqfXNsTE2VTx?= MVzpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> MWmyOFg4PDJ6Nh?=
SW1116  MX3BdI9xfG:|aYOgRZN{[Xl? MkG2NVAh|ryP MU[0PEBp NGDaWVVFVVOR MofX[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MVyyOFg4PDJ6Nh?=
LOVO M17EbmFxd3C2b4Ppd{BCe3OjeR?= NETkS4wyOCEQvF2= NUfqPVY4PDhiaB?= MnvqSG1UVw>? Mlfp[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NYHNV406OjR6N{SyPFY>
RPMI-8226 MV3BdI9xfG:|aYOgRZN{[Xl? MnuyNU8zKM7:TR?= NUnpO3AxPDhxN{KvPVYhcA>? NXK2TGxCTE2VTx?= MnrHbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYr4UpJFOjR6M{OxNFg>
OPM-2  NWC5d3RrSXCxcITvd4l{KEG|c3H5 NF7iRoUyNzJizszN NGjwd5E4Oi97Nj:xNlAhcA>? M{HSW2ROW09? NV;zOJlPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NX7HOYJEOjR6M{OxNFg>
JJN3  MWTBdI9xfG:|aYOgRZN{[Xl? NGTMV28xNjVxMTFOwG0> MXuyOE81QCCq MXnEUXNQ MlvUbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{ezUVI1QDN|MUC4
NCI-H929  MlrBRZBweHSxc3nzJGF{e2G7 NVzaWllROS9{IN88US=> NH;rVJE4Oi97Nj:xNlAhcA>? M4O2NmROW09? NIWxVJJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3GzVlI1QDN|MUC4
RPMI-8226 M3;pVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTTUIQyNzJizszN MoDXNlQwPDhxN{KgbC=> M17oRmROW09? Ml\XZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NUHjfVF1OjR6M{OxNFg>
OPM-2  M3HnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:zS|EwOiEQvF2= NF\jeWIzPC92OD:3NkBp NGLuPHNFVVOR M33RcYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NUTFS3JxOjR6M{OxNFg>
JJN3  M2[1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjZNE42NzFizszN NYC0SnJ4OjRxNEivO|IhcA>? MX\EUXNQ M4P6boFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NUHBbXFpOjR6M{OxNFg>
NCI-H929  MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\TPFEwOiEQvF2= NH\oUJgzPC92OD:3NkBp M{LnfWROW09? MkPYZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M2PNdVI1QDN|MUC4
HeLa NXfEbnp7U2mwYYPlJGF{e2G7 MmHOT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> NYjWTHV6OjR5OECwPVg>
HeLa MojsT4lv[XOnIFHzd4F6 MoHST4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy NGPCOnczPDd6MEC5PC=>
HeLa M3X5OmtqdmG|ZTDBd5NigQ>? M2DxOWtqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> NH7OeXczPDd6MEC5PC=>
HeLa NV;Yb|RXU2mwYYPlJGF{e2G7 MVrLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz M{Xy[|I1PzhyMEm4
NB4 NYjxXotWTnWwY4Tpc44hSXO|YYm= M2DmNFIvPS93L{euOU8yOCEQvF2= NUn2XnFGOjRiaB?= NES2OJZFVVOR MWTpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NFTDcZAzPDR6NEi3NC=>
CD4+ CD25− T  MknISpVv[3Srb36gRZN{[Xl? NYLuZ3pnOS93IN88US=> MUHy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> M2r3cVI1PDd4M{[w
BV-173 NEjlWG9CeG:ydH;zbZMhSXO|YYm= NFTLXYwxNjJ3L{CuOU8xNjd3L{Gg{txO M2jNVlQ5Nzd{L{m2JIg> M2DGReKhWEKV Mlu3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NFrKV3AzPDR{M{[xNy=>
ML-1 NIq0RmdCeG:ydH;zbZMhSXO|YYm= MoDrNE4zPS9yLkWvNE44PS9zIN88US=> NYjTdnJRPDhxN{KvPVYhcA>? MoT4xsBRSlN? NYS0O3RocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NWnNR|I2OjR2MkO2NVM>
HL-60 MmruRZBweHSxc3nzJGF{e2G7 MUmwMlI2NzBwNT:wMlc2NzFizszN M3zDV|Q5Nzd{L{m2JIg> NHPhW|XDqFCEUx?= NW\CWZFDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NW\pVYt7OjR2MkO2NVM>
KG-1a MVTBdI9xfG:|aYOgRZN{[Xl? NFnH[|YxNjJ3L{CuOU8xNjd3L{Gg{txO Mn\OOFgwPzJxOU[gbC=> MmOwxsBRSlN? MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MXmyOFQzOzZzMx?=
BV-173 MnfuSpVv[3Srb36gRZN{[Xl? NV3UXohpOjVyL{WwNI5O M1G3b|Q5KGh? M1zEUuKhWEKV M2rRXolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MXSyOFQzOzZzMx?=
CEM MkHOSpVv[3Srb36gRZN{[Xl? MoHoNlUxNzVyMH7N NYOyNFZrPDhiaB?= MUFCpHBDWw>? MkPSbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MUeyOFQzOzZzMx?=
HL-60 NVrmSmhnTnWwY4Tpc44hSXO|YYm= NGT0XHkzPTBxNUCwcm0> MXK0PEBp M2LSeeKhWEKV MnrWbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NWDNTI8yOjR2MkO2NVM>
ML-1 NF3IVpdHfW6ldHnvckBCe3OjeR?= M2ewO|I2OC93MEDuUS=> M3nwPVQ5KGh? MmG1xsBRSlN? NHLD[JJqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NVvWbHRQOjR2MkO2NVM>
DLD-1 MV;GeY5kfGmxbjDBd5NigQ>? NYXWNGdoOjVyL{WwNI5O MVG0PEBp MXVCpHBDWw>? MVnkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MWqyOFQzOzZzMx?=
HCT-116 NES0OIFHfW6ldHnvckBCe3OjeR?= MX[yOVAwPTBybl2= NH34fWw1QCCq MXpCpHBDWw>? MVTkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MXqyOFQzOzZzMx?=
U937-A/E-9/14/18  NIDURVJCeG:ydH;zbZMhSXO|YYm= MWSwMlAyNzBwMT:xM|ExKM7:TR?= NVjLWJZTPDhiaB?= NUL0NWg1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2T1WlI1OzByNEW2
HT29 NVXCRm05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr5O|IhcA>? Mkn0TWM2OD1zNECwxtEyPzlizszN M4PLPVI1OTd{ME[x
SW48 NVO4SJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPnTnRPPzJiaB?= NGjuZXJKSzVyPUG1MlLDuTZwMjFOwG0> NF7MbVkzPDF5MkC2NS=>
HCT116 NWPsdmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDH[2NIPzJiaB?= MV;JR|UxRTFwN9MxNE41KM7:TR?= NWTQTGFROjRzN{KwOlE>
HepG2 NIDqTWxHfW6ldHnvckBCe3OjeR?= MkjONE42NzFizszN MmXiNlQhcA>? MV;EUXNQ NYPrSFBqfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M3rCR|I1OTR4OEe0
LS174T NHf2bVNHfW6ldHnvckBCe3OjeR?= MX:wMlUwOSEQvF2= M{\tfVI1KGh? NEHDOHJFVVOR MXHs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= MlH1NlQyPDZ6N{S=
HepG2 M3:0eWFxd3C2b4Ppd{BCe3OjeR?= NXrscZluOS9zMD:xNFAh|ryP NIr2c3g4KGR? MkHESG1UVw>? NWfWVmI5cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M37TW|I1OTR4OEe0
LS174T NHjSbVhCeG:ydH;zbZMhSXO|YYm= NGnYd5MyNzFyL{GwNEDPxE1? NHLrc2Y4KGR? NXfhPGtnTE2VTx?= M3fj[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFL3WFkzPDF2Nki3OC=>
QBC-939 NVn2N5ZGSXCxcITvd4l{KEG|c3H5 MWOxM|ExNzFyMDFOwG0> NGX1SXo4KGR? MoHpSG1UVw>? MojIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXuyOFE1Pjh5NB?=
U251 MnzzRZBweHSxc3nzJGF{e2G7 NFjsO5YyNzFyL{GwNEDPxE1? M1P3Xlch\A>? NVvxOWRwTE2VTx?= NWPvN2t4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHLKNVgzPDF2Nki3OC=>
HL-60 NV64U3B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TZelEh|ryP MYK0PEBp M4Hld4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w MmDBNlQxODB|MkS=
MDA‑MB‑453 MoXjSpVv[3Srb36gRZN{[Xl? MmiyNE4zNzFizszN MoXTO|IhcA>? MkKyZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NFywco0zOzh2NEKyPC=>
HCC1569 NV\zTm5bTnWwY4Tpc44hSXO|YYm= NHHJSGQxNjJxMTFOwG0> MWm3NkBp MkHzZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NW\FUmFKOjN6NESyNlg>
BT‑474 NYTNbVJmTnWwY4Tpc44hSXO|YYm= NVvUbnpUOC5{L{Gg{txO Mn34O|IhcA>? M136XoNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NULhclFrOjN6NESyNlg>
AGS NVXXXpRESXCxcITvd4l{KEG|c3H5 NWjqZYc2PS9zMD:yNE82OCEQvF2= MX20POKhcMLi MnLOSG1UVw>? MmTMbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NH7yUXozOzV6Mke4OC=>
A549 NVvh[W96SXCxcITvd4l{KEG|c3H5 MnrNOU8yOC9{MD:1NEDPxE1? M3rET|Q5yqCqwrC= NF7XSplFVVOR NWXnU25TcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NV;4UGo6OjN3OEK3PFQ>
AGS  NXzMNY9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrHT3U2NzFyL{KwM|UxKM7:TR?= MWK0POKhcMLi NEWzNJhFVVOR NWDPTnB7cW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh M37wflI{PTh{N{i0
Kasumi-1 M{Hn[2Fxd3C2b4Ppd{BCe3OjeR?= NHvldIcxNjVizszN M2jRSlQ5yqCqwrC= NUDTNGRo\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MU[yN|Q6OzN2OB?=
OCI-AML3 MoTQRZBweHSxc3nzJGF{e2G7 M4nGd|IvPSEQvF2= NUXRfWZ3PDkEoHlCpC=> M1;ZS4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj M{CzWFI{PDl|M{S4
MV4-11 M2nKUWFxd3C2b4Ppd{BCe3OjeR?= NH2xemkzNjVizszN NUTjUnpGPDkEoHlCpC=> MXvk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MXSyN|Q6OzN2OB?=
NK  NETuWnpEgXSxdH;4bZR6KEG|c3H5 M17ueFAvODJvMkCg{txO NVHBdJJTPSCm MXzk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NFPmV5QzOzN{OEC4PC=>
NK  Mn[5RZBweHSxc3nzJGF{e2G7 M17PeFAvODJvMkCg{txO NX7xTnhHPSCm NILkc|Rl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? Mnr6NlM{OjhyOEi=
NK  NVXsOFJDTnWwY4Tpc44hSXO|YYm= NIizNHcxNjBzLUKwJO69VQ>? NVXQbIZ7PSCm MVPjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl M{Gz[|I{OzJ6MEi4
MOLT4/DNR MkD2SpVv[3Srb36gRZN{[Xl? NWi0ZoNtPSEQvF2= NWfkeWY5PCCm NFj0R4hz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? Ml7xNlMxPjB3N{C=
Jurkat/DOX M2DKOmZ2dmO2aX;uJGF{e2G7 NHO3TFU2KM7:TR?= MXe0JIQ> NGH6PYRz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? M{f1cFI{ODZyNUew
MOLT4/DNR M130cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PROlUh|ryP NVXqVG1qPCCm NUHZRVJpemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NGTCVoczOzB4MEW3NC=>
Jurkat/DOX NIXGZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWi1JO69VQ>? NInkXlc1KGR? NV;BVYdzemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MoT6NlMxPjB3N{C=
ccRCC  MnfBRZBweHSxc3nzJGF{e2G7 M4f1OVAvODFvMUFOwG0> NILoeVE4OiCq NX:4[Gx2TE2VTx?= MXXoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NHnKPHozOjh{NkS2Oy=>
TNBC  MlX2RZBweHSxc3nzJGF{e2G7 Ml72NE4xOS1zMN88US=> NFz3VIE4OiCq MmO2SG1UVw>? MnPDbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? NXXPZZY6OjJ6Mk[0Olc>
A498 MWrBdI9xfG:|aYOgRZN{[Xl? MkT4NE4xOS1zMN88US=> MWq3NkBp MVLEUXNQ MXXpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M{\BdFIzQDJ4NE[3
KIJ265T MV\BdI9xfG:|aYOgRZN{[Xl? M4C1elAvODFvMUFOwG0> NH\PeoI4OiCq M1XqSmROW09? NUnsPHR2cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NV7RWXhPOjJ6Mk[0Olc>
MDA-231 NXnwUY5kSXCxcITvd4l{KEG|c3H5 MVWwMlAyNTFyzszN NIC0SGw4OiCq MlO5SG1UVw>? MoPmbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M3;tdFIzQDJ4NE[3
BT-20 MlLRRZBweHSxc3nzJGF{e2G7 NH3ITWQxNjBzLUGw{txO M{DnN|czKGh? NYHJSYtxTE2VTx?= NGfVSZpqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MUOyNlgzPjR4Nx?=
U937 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3zcYtoPS1{MDFOwG0> NELZTnUzPC92OD:3NkBp NH3nT2RqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NXXBZnpGOjJ5NkewNlE>
HL60 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjGTJBoPS1{MDFOwG0> NIO2b4wzPC92OD:3NkBp MUjpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MWSyNlc3PzB{MR?=
U937 Mkn5RZBweHSxc3nzJGF{e2G7 MnzLNVUh|ryP MX6yOE81QC95MjDo MljzbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYWyNlc3PzB{MR?=
HL60 MV7BdI9xfG:|aYOgRZN{[Xl? Mn[yNVUh|ryP MlWxNlQwPDhxN{KgbC=> NGTiOYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGTEc5IzOjd4N{CyNS=>
LS411N  Mo[5RZBweHSxc3nzJGF{e2G7 MWKwMlUh|ryP NUDIOngzPzJiaB?= MX\pcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? M2HB[VIzPDZzNkm1
MDA-MB-231 NXvnNWpOSXCxcITvd4l{KEG|c3H5 M3vCNFExKM7:TR?= MY[0PEBp NXzPNpdIemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWmyNVg5PzZ7Nx?=
MCF-7  MX;BdI9xfG:|aYOgRZN{[Xl? NF3CZYkyOCEQvF2= MUG0PEBp NYLx[3VzemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlvvNlE5QDd4OUe=
A375 M2SyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMlUh|ryP MVyxM|UwQCCm M3LocolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NH3kPVUzOTd7Nk[yNi=>
SKMEL1 M2jmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmwMlUh|ryP NHTM[WQyNzVxODDk NVzp[oxncW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NH;nZWgzOTd7Nk[yNi=>
SKMEL3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\TXFUxNjVizszN NVHXU2NSOS93L{ig[C=> M4f0eIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MnroNlE4QTZ4MkK=
SKMEL28 NXmwSWwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\kcpkxNjVizszN MYKxM|UwQCCm M1vZdIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NX32boJJOjF5OU[2NlI>
MeWo MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\UZXAxNjVizszN NX3FRYJ{OS93L{ig[C=> NFvBUVlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NUS1U5NzOjF5OU[2NlI>
B16 NHnVPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGxNE42KM7:TR?= NXLEW|JKOS93L{ig[C=> MmfrbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NHyxO3YzOTd7Nk[yNi=>
Ly 1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj1NlQhcA>? MUfJR|UxRTdwMzFOwG0> M1fNOVIyPzd{MES5
Ly 7 NWXGfW9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrueXRTOjRiaB?= NXO2[Y9EUUN3ME2xNE44KM7:TR?= MYiyNVc4OjB2OR?=
Su-DHL6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLqZ4V6OjRiaB?= M{nIXWlEPTExvK6yNEDPxE1? NYe4S5BtOjF5N{KwOFk>
Ly 10 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjnZ3QzPCCq M1KzOWlEPTExvK6yNEDPxE1? NE\RXJczOTd5MkC0PS=>
RIVA NHXaZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTaSY0zPCCq NXPCNIxlUUN3MP-8olIxKM7:TR?= M{nnXVIyPzd{MES5
Su-DHL2 NUPTOJRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXjNlQhcA>? M{HBcWlEPTExvK6yNEDPxE1? MVGyNVc4OjB2OR?=
Ly 1 NWrlNXN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nrOFQ5KGh? MmqyTWM2OD1yLkO0JO69VQ>? NX\ROJMxOjF5N{KwOFk>
Ly 7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7EOFghcA>? NX3Fdmx{UUN3ME2wMlAzPSEQvF2= NX7tUZN2OjF5N{KwOFk>
Su-DHL6 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH24UJo1QCCq NFHQcWZKSzVy78{eNlAh|ryP NWC0dWZHOjF5N{KwOFk>
Ly 10 M4SxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorIOFghcA>? NEf2TFRKSzVyPUGuPEDPxE1? NVL2VnY{OjF5N{KwOFk>
RIVA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPYZWN3PDhiaB?= NUT1XHFNUUN3MP-8olIxKM7:TR?= NIjQdIUzOTd5MkC0PS=>
Su-DHL2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG0PEBp MlzNTWM2OD1zNz60JO69VQ>? MVeyNVc4OjB2OR?=
Ly 1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe1XmY4OiCq MmjTTWM2OD1yLkCxJO69VQ>? M1X5fFIyPzd{MES5
Ly 7 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jFb|czKGh? MoKzTWM2OD1yLkCxPEDPxE1? MmHWNlE4PzJyNEm=
Su-DHL6 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG2O|IhcA>? MmTaTWM2OD1zLk[g{txO MmD2NlE4PzJyNEm=
Ly 10 NXfqPXRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXkO|IhcA>? M1Ha[mlEPTB;MT6yJO69VQ>? M3;iUVIyPzd{MES5
RIVA NFi5cWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC3NkBp Mmf6TWM2OO,:nkKwJO69VQ>? MlHhNlE4PzJyNEm=
Su-DHL2 M3y0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluxO|IhcA>? NGDqS2FKSzVyPUGxMlIh|ryP NEj2bJEzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID